Kaelin U, Hassan AS, Braathen LR, Yawalkar N. Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 2006;55:529-32 (September). (DOI:10.1016/j.jaad.2006.05.062);Treatment of alopecia areata partim universalis with efalizumab

Journal of the American Academy of Dermatology

Volumn 55, Issue 3, 2006, Pages 529-532

  Kaelin, Ursula ^a   Hassan, Akmhal Said ^a   Braathen, Lasser Roger ^a   Yawalkar, Nikil ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD1A MONOCLONAL ANTIBODY; EFALIZUMAB; LEVOTHYROXINE; MONOCLONAL ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ALOPECIA AREATA; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG TOLERABILITY; HAIR LOSS; HUMAN; MALE; PRIORITY JOURNAL;

EID: 33746874475     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.09.026     Document Type: Erratum

References (12)

1. Safavi K.H., Muller S.A., Suman V.J., Moshell A.N., and Melton III L.J. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70 (1995) 628-633
2. Gilhar A., and Kalish R.S. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 5 (2006) 64-69
3. Gilhar A., Landau M., Assy B., Shalaginov R., Serafimovich S., and Kalish R.S. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol 138 (2002) 916-922
4. Norris D.A., Duke R., Whang K., and Middleton M. Immunologic cytotoxicity in alopecia areata: apoptosis of dermal papilla cells in alopecia areata. J Invest Dermatol 104 (1995) 8-9
5. Bodemer C., Peuchmaur M., Fraitaig S., Chatenoud L., Brousse N., and De Prost Y. Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol 114 (2000) 112-116
6. Gilhar A., Landau M., Assy B., Ullmann Y., Shalaginov R., Serafimovich S., and Kalish R.S. Transfer of alopecia areata in the human scalp graft/Prkdc(scid) (SCID) mouse system is characterized by a TH1 response. Clin Immunol 106 (2003) 181-187
7. Papp K.A. Efalizumab: advancing psoriasis management with a novel, targeted T-cell modulator. Drugs Today (Barc) 40 (2004) 889-899
8. Strober B.E., Siu K., Alexis A.F., Kim G., Washenik K., Sinha A., et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 52 (2005) 159-163
9. Ettefagh L., Nedorost S., and Mirmirani P. Alopezia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 140 (2004) 1012
10. Posten W., and Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 141 (2005) 759-760
11. Heffernan M.P., Hurley M.Y., Martin K.S., Smith D.I., and Anadkat M.J. Alefacept for alopecia areata. Arch Dermatol 141 (2005) 1513-1516
12. Nickoloff B.J., and Griffiths C.E. Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata. J Invest Dermatol 96 (1991) 91-92